Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.

Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.

Int J Antimicrob Agents. 2017 Sep;50(3):352-358. doi: 10.1016/j.ijantimicag.2017.03.028. Epub 2017 Jul 6.

2.

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00161-17. doi: 10.1128/AAC.00161-17. Print 2017 Aug.

3.

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.

Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02045-16. doi: 10.1128/AAC.02045-16. Print 2017 Mar.

4.

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.

Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M.

J Antimicrob Chemother. 2016 Oct;71(10):2868-73. doi: 10.1093/jac/dkw214. Epub 2016 Jun 10.

5.

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).

Castanheira M, Messer SA, Rhomberg PR, Pfaller MA.

Diagn Microbiol Infect Dis. 2016 Jun;85(2):200-4. doi: 10.1016/j.diagmicrobio.2016.02.009. Epub 2016 Feb 9.

PMID:
27061369
6.
7.

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).

Pfaller MA, Messer SA, Jones RN, Castanheira M.

J Antibiot (Tokyo). 2015 Sep;68(9):556-61. doi: 10.1038/ja.2015.29. Epub 2015 Apr 22.

PMID:
25899126
8.
9.

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species.

Pfaller MA, Rhomberg PR, Messer SA, Castanheira M.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):259-63. doi: 10.1016/j.diagmicrobio.2014.11.008. Epub 2014 Nov 25.

PMID:
25600842
10.

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.

Castanheira M, Messer SA, Jones RN, Farrell DJ, Pfaller MA.

Int J Antimicrob Agents. 2014 Oct;44(4):320-6. doi: 10.1016/j.ijantimicag.2014.06.007. Epub 2014 Jul 23.

PMID:
25129315
11.

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA.

Mycopathologia. 2014 Aug;178(1-2):1-9. doi: 10.1007/s11046-014-9772-2. Epub 2014 Jun 21.

PMID:
24952015
12.

Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.

Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN.

Diagn Microbiol Infect Dis. 2014 Jun;79(2):198-204. doi: 10.1016/j.diagmicrobio.2014.03.004. Epub 2014 Mar 17.

PMID:
24736096
13.

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.

Pfaller MA, Messer SA, Diekema DJ, Jones RN, Castanheira M.

J Clin Microbiol. 2014 Jan;52(1):108-14. doi: 10.1128/JCM.02481-13. Epub 2013 Oct 23.

14.

Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.

Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN, Pfaller MA.

Antimicrob Agents Chemother. 2014;58(1):577-80. doi: 10.1128/AAC.01674-13. Epub 2013 Oct 14.

15.

In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M.

J Clin Microbiol. 2013 Aug;51(8):2608-16. doi: 10.1128/JCM.00863-13. Epub 2013 Jun 5.

17.

Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA.

Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13. Erratum in: Clin Infect Dis. 2014 Mar;58(5):754.

18.

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2013 Feb;57(2):1065-8. doi: 10.1128/AAC.01588-12. Epub 2012 Dec 10.

19.

Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST).

Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M.

J Antimicrob Chemother. 2013 Apr;68(4):858-63. doi: 10.1093/jac/dks466. Epub 2012 Nov 28.

PMID:
23190764
20.

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.

Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A, Ramani R.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):365-8. doi: 10.1016/j.diagmicrobio.2012.05.008. Epub 2012 Jun 20.

PMID:
22726528
21.

Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.

Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M.

Mycopathologia. 2012 Oct;174(4):259-71. doi: 10.1007/s11046-012-9551-x. Epub 2012 May 13.

PMID:
22580756
22.

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN.

J Clin Microbiol. 2012 Apr;50(4):1199-203. doi: 10.1128/JCM.06112-11. Epub 2012 Jan 25.

23.

Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.

Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN.

Diagn Microbiol Infect Dis. 2011 Nov;71(3):252-9. doi: 10.1016/j.diagmicrobio.2011.07.007. Epub 2011 Sep 13.

PMID:
21917395
24.

Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.

Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN.

J Clin Microbiol. 2011 Nov;49(11):3800-4. doi: 10.1128/JCM.05047-11. Epub 2011 Sep 7.

25.

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods.

Pfaller MA, Watanabe N, Castanheira M, Messer SA, Jones RN.

J Antimicrob Chemother. 2011 Nov;66(11):2581-4. doi: 10.1093/jac/dkr342. Epub 2011 Aug 25.

PMID:
21873291
26.

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Pfaller MA, Duncanson F, Messer SA, Moet GJ, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2011 Nov;55(11):5155-8. doi: 10.1128/AAC.00570-11. Epub 2011 Aug 15.

27.

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.

Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ, Castanheira M.

Diagn Microbiol Infect Dis. 2011 Oct;71(2):167-70. doi: 10.1016/j.diagmicrobio.2011.05.001. Epub 2011 Jun 22.

PMID:
21696907
28.

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M.

Int J Antimicrob Agents. 2011 Jul;38(1):65-9. doi: 10.1016/j.ijantimicag.2011.02.016. Epub 2011 Apr 22.

PMID:
21514797
29.

Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2011 Apr;49(4):1274-9. doi: 10.1128/JCM.02437-10. Epub 2011 Feb 2.

30.
31.

Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2011 Feb;49(2):630-7. doi: 10.1128/JCM.02161-10. Epub 2010 Dec 15.

33.

Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.

Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2011 Feb;55(2):561-6. doi: 10.1128/AAC.01079-10. Epub 2010 Nov 29.

34.
35.

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).

Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):278-83. doi: 10.1016/j.diagmicrobio.2010.06.015. Epub 2010 Sep 16.

PMID:
20846808
36.
37.

Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA.

Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09. Epub 2010 Apr 5.

38.

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN.

J Clin Microbiol. 2010 May;48(5):1592-9. doi: 10.1128/JCM.02445-09. Epub 2010 Mar 24.

39.

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

Diagn Microbiol Infect Dis. 2010 May;67(1):56-60. doi: 10.1016/j.diagmicrobio.2010.01.001. Epub 2010 Mar 5.

PMID:
20207095
40.

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ.

J Clin Microbiol. 2010 Jan;48(1):52-6. doi: 10.1128/JCM.01590-09. Epub 2009 Nov 18.

41.

Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay.

Etienne KA, Gade L, Lockhart SR, Diekema DJ, Messer SA, Pfaller MA, Balajee SA.

J Clin Microbiol. 2009 Dec;47(12):4171-2. doi: 10.1128/JCM.01415-09. Epub 2009 Sep 30.

42.

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ.

J Clin Microbiol. 2009 Dec;47(12):3797-804. doi: 10.1128/JCM.00618-09. Epub 2009 Sep 30.

43.

Candida albicans isolates from APECED patients show decreased susceptibility to miconazole.

Siikala E, Richardson M, Pfaller MA, Diekema DJ, Messer SA, Perheentupa J, Saxén H, Rautemaa R.

Int J Antimicrob Agents. 2009 Dec;34(6):607-9. doi: 10.1016/j.ijantimicag.2009.07.007. Epub 2009 Sep 11. No abstract available.

PMID:
19748230
44.

Screening for Staphylococcus aureus carriage in pregnancy: usefulness of novel sampling and culture strategies.

Andrews JI, Fleener DK, Messer SA, Kroeger JS, Diekema DJ.

Am J Obstet Gynecol. 2009 Oct;201(4):396.e1-5. doi: 10.1016/j.ajog.2009.06.062. Epub 2009 Aug 28.

PMID:
19716114
45.

In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, Pfaller MA.

J Clin Microbiol. 2009 Oct;47(10):3170-7. doi: 10.1128/JCM.00942-09. Epub 2009 Aug 26.

46.

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26.

47.

Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ; ARTEMIS DISK Global Antifungal Surveillance Group.

Diagn Microbiol Infect Dis. 2009 Sep;65(1):27-34. doi: 10.1016/j.diagmicrobio.2009.05.007.

PMID:
19679232
48.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3185-90. doi: 10.1128/JCM.00946-09. Epub 2009 Aug 5.

50.

Congenital candidiasis: confirmation of mother-neonate transmission using molecular analysis techniques.

Tiraboschi IC, Niveyro C, Mandarano AM, Messer SA, Bogdanowicz E, Kurlat I, Lasala MB.

Med Mycol. 2010 Feb;48(1):177-81. doi: 10.3109/13693780902824962.

PMID:
19306215

Supplemental Content

Loading ...
Support Center